Using intermediate cognitive endpoints to facilitate translational research in psychosis

Current Opinion in Behavioral Sciences

Volumn 4, Issue , 2015, Pages 128-135

  Gilmour, Gary ^a   Gastambide, Francois ^a   Marston, Hugh M ^a   Walton, Mark E ^b  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

AMPEROMETRY; BOLD SIGNAL; COGNITION; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; ELECTROENCEPHALOGRAM; HUMAN; LEARNING; MENTAL PATIENT; NEUROTRANSMITTER RELEASE; NONHUMAN; OXYGEN CONCENTRATION; PERCEPTION; PREDICTION; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SPECIES; STATE DEPENDENT LEARNING; TRANSLATIONAL RESEARCH;

EID: 84935921262     PISSN: None     EISSN: 23521546     Source Type: Journal    
DOI: 10.1016/j.cobeha.2015.04.011     Document Type: Review

References (55)

1. Beer M.D. Psychosis: a history of the concept. Compr Psychiatry 1996, 37:273-291.
2. American Psychiatric Association, American Psychiatric Association. DSM-5 Task Force: Diagnostic and statistical manual of mental disorders: DSM-5. edn 5.
3. World Health Organization International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10) 1992, WHO.
4. Murray G.K., Corlett P.R., Clark L., Pessiglione M., Blackwell A.D., Honey G., Jones P.B., Bullmore E.T., Robbins T.W., Fletcher P.C. Substantia nigra/ventral tegmental reward prediction error disruption in psychosis. Mol Psychiatry 2008, 13:239. 267-276.
5. Jeste D.V., Finkel S.I. Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry 2000, 8:29-34.
6. Kelleher I., Jenner J.A., Cannon M. Psychotic symptoms in the general population-an evolutionary perspective. Br J Psychiatry 2010, 197:167.
7. van Os J., Linscott R., Myin-Germeys I., Delespaul P., Krabbendam L. A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. Psychol Med 2009, 39:179-195.
8. Lopez-Munoz F., Alamo C., Cuenca E., Shen W.W., Clervoy P., Rubio G. History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry 2005, 17:113-135.
9. Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry 2007, 18:39-60.
10. Seeman P., Lee T., Chau-Wong M., Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976, 261:717-719.
11. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976, 192:481-483.
12. Richtand N.M., Welge J.A., Logue A.D., Keck P.E., Strakowski S.M., McNamara R.K. Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropsychopharmacology 2007, 32:1715-1726.
13. Modinos G., McGuire P. The prodromal phase of psychosis. Curr Opin Neurobiol 2015, 30:100-105.
14. Wulff S., Pinborg L.H., Svarer C., Jensen L.T., Nielsen M.O., Allerup P., Bak N., Rasmussen H., Frandsen E., Rostrup E., Glenthoj B.Y. Striatal D2/3 binding potential values in drug-naive first-episode schizophrenia patients correlate with treatment outcome. Schizophr Bull 2015, 10.1093/schbul/sbu220.
15. Curran C., Byrappa N., McBride A. Stimulant psychosis: systematic review. Br J Psychiatry 2004, 185:196-204.
16. Paparelli A., Di Forti M., Morrison P.D., Murray R.M. Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of light. Front Behav Neurosci 2011, 5:1.
17. Beaulieu-Boire I., Lang A.E. Behavioral effects of levodopa. Mov Disord 2015, 30:90-102.
18. Howes O., McCutcheon R., Stone J. Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol 2015, 29:97-115.
19. Xu K., Krystal J.H., Ning Y., Chen da C., He H., Wang D., Ke X., Zhang X., Ding Y., Liu Y., et al. Preliminary analysis of positive and negative syndrome scale in ketamine-associated psychosis in comparison with schizophrenia. J Psychiatr Res 2015, 61:64-72.
20. Gobira P.H., Ropke J., Aguiar D.C., Crippa J.A., Moreira F.A. Animal models for predicting the efficacy and side effects of antipsychotic drugs. Rev Bras Psiquiatr 2013, 35(Suppl. 2):S132-S139.
21. Pratt J., Winchester C., Dawson N., Morris B. Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap. Nat Rev Drug Discov 2012, 11:560-579.
22. Arrowsmith J., Miller P. Trial watch: phase II and phase III attrition rates 2011-2012. Nat Rev Drug Discov 2013, 12:569.
23. Cuthbert B.N. The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology. World Psychiatry 2014, 13:28-35.
24. Bell V., Halligan P.W., Ellis H.D. Explaining delusions: a cognitive perspective. Trends Cogn Sci 2006, 10:219-226.
25. Heinz A., Schlagenhauf F. Dopaminergic dysfunction in schizophrenia: salience attribution revisited. Schizophr Bull 2010, 36:472-485.
26. Winton-Brown T.T., Fusar-Poli P., Ungless M.A., Howes O.D. Dopaminergic basis of salience dysregulation in psychosis. Trends Neurosci 2014, 37:85-94.
27. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 2003, 160:13-23.
28. Horvitz J.C., Stewart T., Jacobs B.L. Burst activity of ventral tegmental dopamine neurons is elicited by sensory stimuli in the awake cat. Brain Res 1997, 759:251-258.
29. Ljungberg T., Apicella P., Schultz W. Responses of monkey dopamine neurons during learning of behavioral reactions. J Neurophysiol 1992, 67:145-163.
30. Bunzeck N., Duzel E. Absolute coding of stimulus novelty in the human substantia nigra/VTA. Neuron 2006, 51:369-379.
31. Day J.J., Roitman M.F., Wightman R.M., Carelli R.M. Associative learning mediates dynamic shifts in dopamine signaling in the nucleus accumbens. Nat Neurosci 2007, 10:1020-1028.
32. Montague P.R., Dayan P., Sejnowski T.J. A framework for mesencephalic dopamine systems based on predictive Hebbian learning. J Neurosci 1996, 16:1936-1947.
33. Schultz W., Dayan P., Montague P.R. A neural substrate of prediction and reward. Science 1997, 275:1593-1599.
34. Fletcher P.C., Frith C.D. Perceiving is believing: a Bayesian approach to explaining the positive symptoms of schizophrenia. Nat Rev Neurosci 2009, 10:48-58.
35. Frank M.J. Schizophrenia: a computational reinforcement learning perspective. Schizophr Bull 2008, 34:1008-1011.
36. Smith A.J., Li M., Becker S., Kapur S. Linking animal models of psychosis to computational models of dopamine function. Neuropsychopharmacology 2007, 32:54-66.
37. Corlett P.R., Murray G.K., Honey G.D., Aitken M.R., Shanks D.R., Robbins T.W., Bullmore E.T., Dickinson A., Fletcher P.C. Disrupted prediction-error signal in psychosis: evidence for an associative account of delusions. Brain 2007, 130:2387-2400.
38. Morris R.W., Vercammen A., Lenroot R., Moore L., Langton J.M., Short B., Kulkarni J., Curtis J., O'Donnell M., Weickert C.S., Weickert T.W. Disambiguating ventral striatum fMRI-related BOLD signal during reward prediction in schizophrenia. Mol Psychiatry 2012, 17:235. 280-289.
39. Nielsen M.O., Rostrup E., Wulff S., Bak N., Broberg B.V., Lublin H., Kapur S., Glenthoj B. Improvement of brain reward abnormalities by antipsychotic monotherapy in schizophrenia. Arch Gen Psychiatry 2012, 69:1195-1204.
40. Francois J., Huxter J., Conway M.W., Lowry J.P., Tricklebank M.D., Gilmour G. Differential contributions of infralimbic prefrontal cortex and nucleus accumbens during reward-based learning and extinction. J Neurosci 2014, 34:596-607.
41. Bernacer J., Corlett P.R., Ramachandra P., McFarlane B., Turner D.C., Clark L., Robbins T.W., Fletcher P.C., Murray G.K. Methamphetamine-induced disruption of frontostriatal reward learning signals: relation to psychotic symptoms. Am J Psychiatry 2013, 170:1326-1334.
42. Li J., Ishiwari K., Conway M.W., Francois J., Huxter J., Lowry J.P., Schwarz A.J., Tricklebank M., Gilmour G. Dissociable effects of antipsychotics on ketamine-induced changes in regional oxygenation and inter-regional coherence of low frequency oxygen fluctuations in the rat. Neuropsychopharmacology 2014, 39:1635-1644.
43. Clark J.J., Sandberg S.G., Wanat M.J., Gan J.O., Horne E.A., Hart A.S., Akers C.A., Parker J.G., Willuhn I., Martinez V., et al. Chronic microsensors for longitudinal, subsecond dopamine detection in behaving animals. Nat Methods 2010, 7:126-129.
44. Fusar-Poli P., Bonoldi I., Yung A.R., Borgwardt S., Kempton M.J., Valmaggia L., Barale F., Caverzasi E., McGuire P. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 2012, 69:220-229.
45. Stone J.M., Howes O.D., Egerton A., Kambeitz J., Allen P., Lythgoe D.J., O'Gorman R.L., McLean M.A., Barker G.J., McGuire P. Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. Biol Psychiatry 2010, 68:599-602.
46. Woodward N.D., Cowan R.L., Park S., Ansari M.S., Baldwin R.M., Li R., Doop M., Kessler R.M., Zald D.H. Correlation of individual differences in schizotypal personality traits with amphetamine-induced dopamine release in striatal and extrastriatal brain regions. Am J Psychiatry 2011, 168:418-426.
47. Stone J.M., Raffin M., Morrison P., McGuire P.K. Review: the biological basis of antipsychotic response in schizophrenia. J Psychopharmacol 2010, 24:953-964.
48. Lindenmayer J.P. Treatment refractory schizophrenia. Psychiatr Q 2000, 71:373-384.
49. Demjaha A., Egerton A., Murray R.M., Kapur S., Howes O.D., Stone J.M., McGuire P.K. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry 2014, 75:e11-e13.
50. Schobel S.A., Chaudhury N.H., Khan U.A., Paniagua B., Styner M.A., Asllani I., Inbar B.P., Corcoran C.M., Lieberman J.A., Moore H., Small S.A. Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron 2013, 78:81-93.
51. Barkus C., Sanderson D.J., Rawlins J.N., Walton M.E., Harrison P.J., Bannerman D.M. What causes aberrant salience in schizophrenia? A role for impaired short-term habituation and the GRIA1 (GluA1) AMPA receptor subunit. Mol Psychiatry 2014, 19:1060-1070.
52. Grace A.A. Dopamine system dysregulation by the hippocampus: implications for the pathophysiology and treatment of schizophrenia. Neuropharmacology 2012, 62:1342-1348.
53. Hagele C., Schlagenhauf F., Rapp M., Sterzer P., Beck A., Bermpohl F., Stoy M., Strohle A., Wittchen H.U., Dolan R.J., Heinz A. Dimensional psychiatry: reward dysfunction and depressive mood across psychiatric disorders. Psychopharmacology (Berl) 2015, 232:331-341.
54. Rutledge R.B., Dean M., Caplin A., Glimcher P.W. Testing the reward prediction error hypothesis with an axiomatic model. J Neurosci 2010, 30:13525-13536.
55. Knutson B., Heinz A. Probing psychiatric symptoms with the monetary incentive delay task. Biol Psychiatry 2015, 77:418-420.